NCT00095823 - A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder | Biotech Hunter

Enrollment

1,200

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions

Major Depressive Disorder

Interventions

DRUG

Antidepressant + Placebo

Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

DRUG

Antidepressant + Aripiprazole

Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

Trial Locations (20)

Unknown

Local Institution, Garden Grove

Local Institution, Northridge

Local Institution, Washington D.C.

Local Institution, Jacksonville

Local Institution, Chicago

Local Institution, Edwardsville

Local Institution, Rockville

Local Institution, Springfield

Local Institution, Farmington Hills

Local Institution, Okemos

Local Institution, Staten Island

Local Institution, Portland

Local Institution, Philadelphia

Local Institution, Austin

Local Institution, Salt Lake City

Local Institution, Woodstock

Local Institution, Charlottesville

Local Institution, Bellevue

Local Institution, Seattle

Local Institution, Middleton